Actinium Pharmaceuticals Inc (ATNM) Stock Price, Quote & News

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle c...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 677 3870

Website: www.actiniumpharma.com

Address:

100 Park Avenue, 23rd Floor, New York, United States

Arneyjivers Jul. 1 at 3:15 PM

$ATNM you know, you're in trouble when the daily volume is less than total amount of shares, you hold.

1 · Reply

greencheese500 Jul. 1 at 2:23 PM

$ATNM NEWS This week or next week?

2 · Reply

Pickerbefore Jun. 30 at 8:28 PM

$ATNM penny stock now. Doomed by the CEO.

0 · Reply

Pickerbefore Jun. 30 at 4:34 PM

$ATNM dumbest CEO on Earth. another reverse split may be coming soon.

0 · Reply

Sciguy67 Jun. 30 at 3:05 PM

$ATNM hmm 20 to 1 rs around the corner

2 · Reply

englishkaren Jun. 30 at 2:23 PM

$ATNM Look at us at #30 of the Top 45 Companies Leading the Acute Myeloid Leukemia Market https://www.sphericalinsights.com/blogs/world-s-top-45-companies-in-acute-myeloid-leukemia-market-2025-industry-intelligence-report-by-spherical-insights-2026-2035

1 · Reply

StockKing_2 Jun. 29 at 6:01 PM

$ATNM great - we’ve got a three day weekend coming up. I’m sure Actinium is busy working on some press releases for Thursday night release.

1 · Reply

tjm1 Jun. 29 at 5:33 PM

$ATNM we are heading towards delisting while Relmada upgrades to the Russel 3000......once again, nice job Seth!

1 · Reply

englishkaren Jun. 29 at 5:13 PM

$ATNM Trial registered on ANZCTR https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12625001362482

2 · Reply

fede5910 Jun. 29 at 12:15 PM

$ATNM How I would like ATNM to let me know if the first patient in Australia or South Africa has already been treated.

3 · Reply

Actinium Pharmaceuticals Slides: Investor presentation

2026-06-03T13:39:19.000Z - 4 weeks ago

Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026

Jun 3, 2026, 8:00 AM EDT - 4 weeks ago

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Jun 3, 2026, 7:25 AM EDT - 4 weeks ago

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models

2026-06-01T12:52:17.000Z - 4 weeks ago

Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

CNTA

2026-06-01T11:12:02.000Z - 4 weeks ago

Actinium Pharmaceuticals presents new radiochemistry data at SNMMI

Jun 1, 2026, 7:00 AM EDT - 4 weeks ago

Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates

2026-05-29T21:41:04.000Z - 4 weeks ago

Actinium Pharmaceuticals receives two patent allowances from CIPO

May 29, 2026, 5:31 PM EDT - 4 weeks ago

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

May 29, 2026, 5:30 PM EDT - 4 weeks ago

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

May 27, 2026, 9:00 AM EDT - 5 weeks ago

NorthStar and QSA Global Announce Multi-Year Strategic Partnership to Strengthen Actinium-225 Supply Chain for Targeted Alpha Therapies

May 15, 2026, 7:00 AM EDT - 6 weeks ago

Actinium Pharmaceuticals Slides: Investor presentation

May 8, 2026, 7:00 AM EDT - 7 weeks ago

Actinium Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 2 months ago

Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

2026-04-22T11:29:41.000Z - 2 months ago

Actinium presents data from Actimab-A studies at AACR

2026-04-22T11:23:31.000Z - 2 months ago

Actinium presents preclinical results for ATNM-400 at AACR

Apr 22, 2026, 7:00 AM EDT - 2 months ago

Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting

Apr 22, 2026, 7:00 AM EDT - 2 months ago

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

Apr 15, 2026, 8:00 AM EDT - 2 months ago

NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225

Apr 9, 2026, 7:00 AM EDT - 2 months ago

Actinium Pharmaceuticals Slides: Investor presentation

Apr 6, 2026, 7:30 AM EDT - 3 months ago

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Actinium Pharmaceuticals Annual report: Q4 2025

Feb 17, 2026, 8:00 AM EST - 4 months ago

BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

2025-12-12T13:50:27.000Z - 7 months ago

Actinium Pharmaceuticals presents new data on anti-tumor activity of ATNM-400

Dec 12, 2025, 8:45 AM EST - 7 months ago

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

2025-12-01T13:50:36.000Z - 7 months ago

Actinium Pharmaceuticals announces preclinical data for ATNM-400

Dec 1, 2025, 8:45 AM EST - 7 months ago

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

Nov 17, 2025, 8:30 AM EST - 8 months ago

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

NVS

Nov 14, 2025, 4:00 PM EST - 8 months ago

Actinium Pharmaceuticals Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 8 months ago

Actinium Pharmaceuticals Proxy statement: Proxy Filing

2025-10-27T11:15:51.000Z - 8 months ago

Actinium Pharmaceuticals’ ATNM-400 shows superior anti-tumor activity

AZN JNJ

Oct 27, 2025, 7:00 AM EDT - 8 months ago

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-10-24T12:35:37.000Z - 8 months ago

Actinium presents preclinical data for ATNM-400

Oct 24, 2025, 8:30 AM EDT - 8 months ago

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

2025-10-13T16:25:11.000Z - 9 months ago

Actinium Pharmaceuticals to announces preclinical data from ATNM-400 program

Oct 13, 2025, 12:10 PM EDT - 9 months ago

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 8:30 AM EDT - 9 months ago

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Aug 8, 2025, 7:00 AM EDT - 11 months ago

Actinium Pharmaceuticals Quarterly report: Q2 2025

2025-07-31T12:42:35.000Z - 11 months ago

Actinium Pharmaceuticals’ ATNM-400 shows improved survival in prostate cancer

Jul 31, 2025, 8:30 AM EDT - 11 months ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

2025-06-23T17:33:54.000Z - 1 year ago

Actinium highlights expanded data set for ATNM-400 in prostate cancer

Jun 23, 2025, 11:30 AM EDT - 1 year ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 12, 2025, 11:00 AM EDT - 1 year ago

Actinium Pharmaceuticals Transcript: Life Sciences Investor Forum

2025-05-20T12:31:41.000Z - 1 year ago

ATNM Lawsuit Alert! Class Action Lawsuit Against Actinium Pharmaceuticals

May 9, 2025, 12:00 AM EDT - 1 year ago

Actinium Pharmaceuticals Quarterly report: Q1 2025

2025-05-06T12:50:27.000Z - 1 year ago

Actinium enrolls first patient on the trial studying Iomab-ACT

May 6, 2025, 8:45 AM EDT - 1 year ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Apr 30, 2025, 7:25 AM EDT - 1 year ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

2025-04-28T12:47:44.000Z - 1 year ago

Actinium Pharmaceuticals’ ATNM-400 shows efficacy in prostate cancer study

NVS

2025-04-28T12:13:37.000Z - 1 year ago

Actinium’s Actimab-A shows antileukemic activity in AML models

SNDX

Apr 10, 2025, 9:00 AM EDT - 1 year ago

Actinium Pharmaceuticals Transcript: 15th Annual LD Micro Invitational 2025

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Actinium Pharmaceuticals Annual report: Q4 2024

2025-03-25T19:20:49.000Z - 1 year ago

Actinium Pharmaceuticals enters supply pact with Eckert & Ziegler

Arneyjivers Jul. 1 at 3:15 PM

$ATNM you know, you're in trouble when the daily volume is less than total amount of shares, you hold.

1 · Reply

greencheese500 Jul. 1 at 2:23 PM

$ATNM NEWS This week or next week?

2 · Reply

Pickerbefore Jun. 30 at 8:28 PM

$ATNM penny stock now. Doomed by the CEO.

0 · Reply

Pickerbefore Jun. 30 at 4:34 PM

$ATNM dumbest CEO on Earth. another reverse split may be coming soon.

0 · Reply

Sciguy67 Jun. 30 at 3:05 PM

$ATNM hmm 20 to 1 rs around the corner

2 · Reply

englishkaren Jun. 30 at 2:23 PM

1 · Reply

StockKing_2 Jun. 29 at 6:01 PM

$ATNM great - we’ve got a three day weekend coming up. I’m sure Actinium is busy working on some press releases for Thursday night release.

1 · Reply

tjm1 Jun. 29 at 5:33 PM

$ATNM we are heading towards delisting while Relmada upgrades to the Russel 3000......once again, nice job Seth!

1 · Reply

englishkaren Jun. 29 at 5:13 PM

$ATNM Trial registered on ANZCTR https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12625001362482

2 · Reply

fede5910 Jun. 29 at 12:15 PM

$ATNM How I would like ATNM to let me know if the first patient in Australia or South Africa has already been treated.

3 · Reply

gooddoggie Jun. 29 at 8:44 AM

$ATNM Wow. I remember when $25 was a nice living. But it’s just a number now. Meaningless for comparison to other times. The ones who are being hurt ✋🏻 are us poor suckers who live on retirement based on yesterday’s dollar value.

1 · Reply

johnny4cures Jun. 29 at 2:34 AM

$ATNM see this

1 · Reply

johnny4cures Jun. 29 at 2:26 AM

$ATNM "7. FDA Fast Track / Breakthrough Evaluation What happens: IO‑reset signals from Actimab‑A Zr‑89 targeting signals from ATNM‑400 Ac‑225 safety validated Theranostic logic validated Why it matters: FDA begins accelerated‑pathway discussions. 8. Registrational Phase 2/2b Allowed What happens: Smaller trials Faster enrollment Biomarker‑driven cohorts Adaptive expansion allowed Why it matters: Approval timeline moves into 2029–2030, not 2033–2034."

0 · Reply

johnny4cures Jun. 29 at 12:24 AM

$ATNM see what co p says 3. First‑in‑Human Dosing (Australia) What happens: First Ac‑225 patient dosed Zr‑89 imaging performed Biodistribution captured Organ safety measured PSA/tumor response monitored Why it matters: This counts as FIH for FDA and Orbis.

0 · Reply

gooddoggie Jun. 28 at 9:24 PM

$ATNM @bobbychef I’m VERY excited about the upcoming TayTay and Travis wedding!!! Are you?

2 · Reply

Pinto72 Jun. 28 at 6:55 PM

$ATNM They don’t even produce Acc225🚀🚀🚀 Congrats @johnny4skin! BANKRUPTCY AS SOO!!! eXtReEmLeE bUlLiSh!!!🤣🤣🤣🤣

0 · Reply

Pickerbefore Jun. 28 at 4:22 PM

$ATNM this stock has been an embarrassment to many portfolios. Seth has not ever delivered, and the stock is down 95% while he was CEO. Why is this fool still employed and why haven't they hired someone capable of delivering? It should be unlawful for the CEO to sit on the BOD.

0 · Reply

gooddoggie Jun. 28 at 2:43 PM

$ATNM Sup

1 · Reply

Geert07 Jun. 27 at 1:00 PM

$ATNM Kickin’ the can down the road since 2000

0 · Reply

johnny4cures Jun. 27 at 4:33 AM

$ATNM co p says ⭐ 3. For radiopharmaceuticals, Australia is the gold standard for FIH Australia is the fastest country in the world for: radiopharmaceutical ethics approval radiopharmaceutical site activation radiopharmaceutical imaging (Zr‑89, PSMA PET) radiopharmaceutical dose escalation This means: ✔ FIH happens earlier ✔ safety emerges earlier ✔ biodistribution emerges earlier ✔ dosimetry emerges earlier ✔ tumor targeting emerges earlier And because it’s an Orbis country: ⭐ FDA sees the same FIH data months earlier than if the trial were U.S.‑only. ⭐ 4. FIH is defined by the isotope + construct, not the country

1 · Reply

englishkaren Jun. 27 at 12:34 AM

$ATNM closed at 99 cents today. $31M market cap. I value this company at $2.5B to $3B minimum based on comparable M&A. RayzeBio $4.1B. Fusion $2.4B. Point $1.4B. None had what ATNM has. Signed GMP facility at Albert Einstein. HER3 Phase 1 trial active in Australia. IND filed. CMO in place. KRAS data. 250 patents. $42M cash. No debt. Pluvicto doing $2B a year in the same space. The market is pricing this like it has nothing. It has everything except human efficacy data. That is coming 2H:2026. Claude today.

7 · Reply

Investfaithfully Jun. 26 at 9:39 PM

$ATNM buy with both hands at this level our surprises coming soon……

0 · Reply

Market Cap	31.06M
Revenue (ttm)	90,000.00
Net Income (ttm)	-33.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-37,655.55%
Debt to Equity Ratio	0.00

Volume	54,877
Avg Vol	179,100
Day's Range	N/A - N/A
Shares Out	31.38M
Stochastic %K	24%
Beta	-0.06
Analysts	Strong Sell
Price Target	$5.00